Class Action Lawsuit Launched Against BioAge Labs, Inc. for Securities Fraud Allegations

Class Action Lawsuit Against BioAge Labs, Inc.

On February 25, 2025, it was announced that a class action securities lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) by the legal firm Levi & Korsinsky, LLP. This case arises from significant allegations of securities fraud that have severely impacted investors in the biotechnology firm.

Background on the Lawsuit

The class action seeks to compensate investors who sustained financial losses after acquiring shares in BioAge, particularly those who purchased stock following the company's initial public offering (IPO) around September 26, 2024. The crucial turning point occurred on December 6, 2024, when BioAge revealed the discontinuation of its STRIDES Phase 2 clinical trial for azelaprag. This announcement came as a shock to many, especially following the company's assertions of the drug's potential during its IPO presentation.

The sudden halt of the trial was attributed to safety concerns over elevated liver transaminase levels among trial participants. Consequently, the stock price plummeted from $20.09 per share on December 6, 2024, to a mere $4.65 the following day—an alarming 76.8% drop that affected many investors.

Who Can Claim?

Investors who acquired BioAge shares in the relevant time frame and experienced a financial loss are eligible to request appointment as lead plaintiff in the lawsuit until March 10, 2025. However, it is important to note that participation in any recovery does not obligate individuals to take on this role as lead plaintiff.

Additionally, the lawsuit brings an encouraging aspect. Investors who qualify as class members stand to gain compensation without any out-of-pocket expenses, making it an attractive option to seek redress without financial risk.

Why Choose Levi & Korsinsky?

The legal team at Levi & Korsinsky has a long-standing reputation for securing substantial settlements for aggrieved shareholders over the last two decades. With a dedicated group of more than 70 professionals specializing in complex securities litigation, they have been recognized in ISS Securities Class Action Services' Top 50 Report as one of the leading securities litigation firms in the United States for seven consecutive years. Their extensive experience suggests that they are well-equipped to handle the intricacies of this case.

How to Get Involved

Affected BioAge investors who wish to explore their legal options can reach out to Joseph E. Levi, Esq. or Ed Korsinsky, Esq. directly via email at [email protected] or through their office line at (212) 363-7500. For more detailed information regarding this class action lawsuit, individuals can visit the Levi & Korsinsky website and follow the provided link for submission. This offers a streamlined opportunity for investors to reclaim what they have lost due to the alleged mismanagement surrounding BioAge's disclosures.

In summary, as the class action against BioAge Labs, Inc. progresses, investors who have suffered losses are encouraged to come forth, assess the situation, and take the necessary steps to assert their rights under the protective umbrella of securities laws.